[go: up one dir, main page]

WO2025222100A3 - Cd3 binding proteins, nucleic acids encoding such proteins, and methods for the preparation and use thereof - Google Patents

Cd3 binding proteins, nucleic acids encoding such proteins, and methods for the preparation and use thereof

Info

Publication number
WO2025222100A3
WO2025222100A3 PCT/US2025/025335 US2025025335W WO2025222100A3 WO 2025222100 A3 WO2025222100 A3 WO 2025222100A3 US 2025025335 W US2025025335 W US 2025025335W WO 2025222100 A3 WO2025222100 A3 WO 2025222100A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
methods
preparation
nucleic acids
acids encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/025335
Other languages
French (fr)
Other versions
WO2025222100A2 (en
Inventor
Alexander John MARTINKO
David Geoffrey KUGLER
Burcu YIGIT
Mary MATHIEU
Prasuna PALURU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cartography Biosciences Inc
Original Assignee
Cartography Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cartography Biosciences Inc filed Critical Cartography Biosciences Inc
Publication of WO2025222100A2 publication Critical patent/WO2025222100A2/en
Publication of WO2025222100A3 publication Critical patent/WO2025222100A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

CD3-binding proteins, CDR sequences, variable domain sequences, and related compositions, and methods for their use and manufacture.
PCT/US2025/025335 2024-04-19 2025-04-18 Cd3 binding proteins, nucleic acids encoding such proteins, and methods for the preparation and use thereof Pending WO2025222100A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463636680P 2024-04-19 2024-04-19
US63/636,680 2024-04-19

Publications (2)

Publication Number Publication Date
WO2025222100A2 WO2025222100A2 (en) 2025-10-23
WO2025222100A3 true WO2025222100A3 (en) 2025-12-04

Family

ID=97404433

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/025335 Pending WO2025222100A2 (en) 2024-04-19 2025-04-18 Cd3 binding proteins, nucleic acids encoding such proteins, and methods for the preparation and use thereof

Country Status (1)

Country Link
WO (1) WO2025222100A2 (en)

Also Published As

Publication number Publication date
WO2025222100A2 (en) 2025-10-23

Similar Documents

Publication Publication Date Title
WO2023166418A3 (en) Multispecific antibodies binding to il-4, il-13 and/or tslp and uses thereof
EP4524236A3 (en) Anti-vegf protein compositions and methods for producing the same
PH12021500024A1 (en) Bispecific antigen binding molecules comprising anti-fap clone 212
CN114502591A (en) Antibodies targeting BCMA, bispecific antibodies and uses thereof
WO1990007862A3 (en) Generation and selection of novel dna-binding proteins and polypeptides
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
IL145813A0 (en) SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ1
WO2021127200A8 (en) Ilt3-binding agents and methods of use thereof
WO2021173896A8 (en) Materials and methods for modulating an immune response
WO2003033654A3 (en) Direct targeting binding proteins
WO2020139926A3 (en) Anti-ctla4 antibodies and methods of use thereof
WO2004029093A3 (en) Humanized anti-granulocyte mn-3 antibody and uses thereof
DE60139542D1 (en) METHODS OF PREPARING HUMAN MONOCLONAL ANTIBODIES
WO2019217145A8 (en) Anti-dll3 antibodies and uses thereof
WO2004093808A3 (en) Novel tumor-associated antigens
WO2021262597A3 (en) Lair-1-binding agents and methods of use thereof
WO2002062957A3 (en) Ter sites and ter binding proteins
WO2024163630A3 (en) Anti-cdh17 antibodies and use of the same
WO2024086617A3 (en) Ph-dependent anti-cd3 antibodies and methods relating thereto
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
ZA202404271B (en) Bispecific cd16a binders
WO2025222100A3 (en) Cd3 binding proteins, nucleic acids encoding such proteins, and methods for the preparation and use thereof
WO2002063010A3 (en) Method of producing recombinant antibodies against tumors
WO2024026029A3 (en) Lipid nanoparticles for immunotherapy
WO2005095453A3 (en) Specific binding members against synaptophysin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25788431

Country of ref document: EP

Kind code of ref document: A2